Advanced search
Publication Cover
Journal of Asthma Volume 61, 2024 - Issue 3
Submit an article Journal homepage
280
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Dual biologics therapy in a patient with severe asthma and chronic urticaria: a case report and review of the literature

Ozge Can BostanDepartment of Chest Diseases, Division of Allergy and Immunology, Hacettepe University School of Medicine, Ankara, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4528-5404View further author information
, MDORCID Icon,
Gul KarakayaDepartment of Chest Diseases, Division of Allergy and Immunology, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
, MD,
Ali Fuat KalyoncuDepartment of Chest Diseases, Division of Allergy and Immunology, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
, MD &
Ebru DamadogluDepartment of Chest Diseases, Division of Allergy and Immunology, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
, MD
Pages 260-264 | Received 07 Aug 2023, Accepted 14 Sep 2023, Published online: 20 Sep 2023

References

  • Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506.
  • Frøssing L, Silberbrandt A, Von Bülow A, Backer V, Porsbjerg C. The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma. J Allergy Clin Immunol Pract. 2021;9(3):1267–1275. doi:10.1016/j.jaip.2020.09.051.
  • Paçacı Çetin G, Kepil Özdemir S, Can Bostan Ö, Öztop N, Çelebi Sözener Z, Karakaya G, Gelincik Akkor A, Yılmaz İ, Mungan D, Bavbek S, et al. Ağır astım tedavisinde biyolojikler: güncel durum raporu 2023 [Biologics for the treatment of severe asthma: current status report 2023]. Tuberk Toraks. 2023;71(2):176–187. doi:10.5578/tt.20239921.
  • Saini SS, Kaplan AP. Chronic spontaneous urticaria: the Devil’s Itch. J Allergy Clin Immunol Pract. 2018;6(4):1097–1106. doi:10.1016/j.jaip.2018.04.013.
  • Giménez-Arnau AM, DeMontojoye L, Asero R, Cugno M, Kulthanan K, Yanase Y, Hide M, Kaplan AP. The pathogenesis of chronic spontaneous Urticaria: the Role of Infiltrating Cells. J Allergy Clin Immunol Pract. 2021;9(6):2195–2208. doi:10.1016/j.jaip.2021.03.033.
  • Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389–401. doi:10.1111/all.15603.
  • Isik SR, Karakaya G, Celikel S, Demir AU, Kalyoncu AF. Association between asthma, rhinitis and NSAID ­hypersensitivity in chronic urticaria patients and prevalence rates. Int Arch Allergy Immunol. 2009;150(3):299–306. doi:10.1159/000222683.
  • Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract. 2021;9(3):1067–1078. doi:10.1016/j.jaip.2020.11.043.
  • Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. Allergy Asthma Clin Immunol. 2009;5(1):10.
  • Doğruman Al F, Adişen E, Kuştimur S, Gürer MA. Urtiker Etyolojisinde Protozoonlarin Yeri [The role of protozoan parasites in etiology of urticaria]. Turkiye Parazitol Derg. 2009;33(2):136–139.
  • Ortega G, Tongchinsub P, Carr T. Combination biologic therapy for severe persistent asthma. Ann Allergy Asthma Immunol. 2019;123(3):309–311. doi:10.1016/j.anai.2019.06.013.
  • Domingo C, Pomares X, Morón A, Sogo A. Dual monoclonal antibody therapy for a severe asthma patient. Front Pharmacol. 2020;11:587621. doi:10.3389/fphar.2020.587621.
  • Fox HM, Rotolo SM. Combination anti-IgE and anti-IL5 therapy in a pediatric patient with severe persistent asthma. J Pediatr Pharmacol Ther. 2021;26(3):306–310.
  • Serajeddini H, Venegas Garrido C, Bhalla A, Kjarsgaard M, Huang C, LaVigne N, Radford K, Zhang K, Ho T, Svenningsen S, et al. A case series of dual biologics therapy for severe asthma. J Allergy Clin Immunol Pract. 2023;11(1):335–340.e2. doi:10.1016/j.jaip.2022.09.036.
  • Baccelli A, Koćwin M, Parazzini EM, Rinaldo RF, Centanni S. Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study. J Asthma. 2023;60(5):1050–1053. doi:10.1080/02770903.2022.2109162.
  • Malik M, Jones B, Williams E, Kurukulaaratchy R, Holroyd C, Mason A. Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series. Rheumatol Adv Pract. 2023;7(1):rkad018.
  • Lommatzsch M, Suhling H, Korn S, Bergmann K-C, Schreiber J, Bahmer T, Rabe KF, Buhl R, Virchow JC, Milger K, et al. Safety of combining biologics in severe asthma: asthma-related and unrelated combinations. Allergy. 2022;77(9):2839–2843. doi:10.1111/all.15379.
  • Khan D, Nicolaides R. Patient outcomes and safety of dual biologic therapies. J Allergy Clin Immunol. 2020;145(2):AB23. doi:10.1016/j.jaci.2019.12.798.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.